Net Pals Net Pals
Search Results
See All Results
  • Join
    Sign In
    Sign Up
    Search
    Night Mode

Search

Discover new people, create new connections and make new friends

  • News Feed
  • EXPLORE
  • Pages
  • Groups
  • Events
  • Reels
  • Blogs
  • Market
  • Offers
  • Jobs
  • Posts
  • Blogs
  • Users
  • Pages
  • Groups
  • Events
  • mahir007 added blog Other
    2026-11-16 13:21:25 - Translate -
    Biotechnology Market Size, Share, Trends & Forecast 2033
    Latest Insights on Executive Summary Biotechnology Market Share and SizeCAGR Value The global biotechnology market was valued at USD 1.70 billion in 2024 and is expected to reach USD 13.03 billion by 2032 The Biotechnology Market report is the best to know the trends and opportunities in Biotechnology Market The forecast, analysis, evaluations, and estimations carried out in this...
    0 Comments 0 Shares 22 Views 0 Reviews
    Please log in to like, share and comment!
  • SaadIqbal added blog Health
    2026-10-26 15:58:11 - Translate -
    Danaher (DHR) raised its 2026 profit outlook as core sales grew only 3.0%
    Adjusted earnings per share rose 11.5% in the third quarter while core sales grew 3.0%, and the full-year range moved up by less than the quarter's gain. Cash flow and segment mix tell a narrower story. Danaher Corporation (DHR) reported third-quarter 2026 results on October 21 and raised its full-year adjusted earnings guidance. Adjusted diluted earnings per share reached $2.11, up from $1.89...
    0 Comments 0 Shares 1K Views 0 Reviews
    Please log in to like, share and comment!
  • RobertMitchell added blog Health
    2026-10-23 19:35:08 - Translate -
    Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease tests
    Roth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...
    0 Comments 0 Shares 1K Views 0 Reviews
    Please log in to like, share and comment!
© 2026 Net Pals English
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Terms Privacy Cookies Acceptable Use Contact Us Directory